Codexis Stock Earnings Reports

Codexis reported a strong Q1 2026 with revenue of $15.2M (vs. $7.5M a year ago) driven primarily by recognition of a Merck technology transfer agreement. The company is positioning its ECO Synthesis enzymatic platform as a scalable, more sustainable alternative to traditional solid-phase oligonucleotide (siRNA) manufacturing and highlighted a new capability to control stereochemistry at both ends of siRNA molecules — a potential driver of improved product quality and potency. Commercial traction includes a sales pipeline of 50+ opportunities with ~40 companies, ongoing engagements with multiple CDMO partners, and supply relationships for 13 approved small-molecule products (including recent involvement in Merck's islatravir supply). Financials: product gross margin improved to 71% in Q1, R&D and SG&A declined vs. prior year, net loss narrowed to $8.7M, and cash was $65.1M at quarter end. Codexis reiterated 2026 revenue guidance of $72M–$76M and expects cash to fund operations and capex through end of 2027, which includes the planned GMP facility retrofit in Hayward (targeted operational by end of 2027). Operational priorities: demonstrate ECO Synthesis value via customer contracts and licensing, scale platform to 0.5 kg by year-end 2026 (and beyond), continue CDMO partnerships, present stereochemistry and sustainability data at TIDES, and pursue regulatory engagement including FDA Emerging Technologies and potential Advanced Manufacturing Technologies designation. Risks noted include typical scale-up and process control challenges, competition for manufacturing capacity, and reliance on successful commercialization partnerships and customer adoption.